90-day CGM implant receives recommendation for FDA approval

Eversense, a continuous glucose monitor from Senseonics that is implanted subcutaneously in the arm for up to three months, has been recommended for approval by an FDA advisory committee.

Source: 90-day CGM implant receives recommendation for FDA approval